CD70 and nonpapillary renal cell carcinoma: The phase 1 TRAVERSE study (NCT04696731) is currently investigating an anti-CD70 allogenic CAR-T preparation (ALLO-316) for patients with advanced ccRCC who have progressed on ICI and TKI therapies.